SARS-CoV-2 envelope protein

A short integral membrane protein

Also Known As:

envelope protein, SARS-CoV-2; E protein, SARS-CoV-2; E protein, severe acute respiratory syndrome coronavirus 2; envelope protein, 2019 novel coronavirus; envelope protein, 2019-nCoV; envelope protein, COVID-19 virus; envelope protein, COVID19 virus; envelope protein, severe acute respiratory syndrome coronavirus 2

Networked: 11 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Viral Proteins: 4250
    - Viral Structural Proteins: 171
      - Viral Envelope Proteins: 291
        Coronavirus Envelope Proteins
        SARS-CoV-2 envelope protein: 11

Experts

1.	Babini, Gabriele: 2 articles (11/2020 - 05/2020)
2.	De Maio, Flavio: 2 articles (11/2020 - 05/2020)
3.	Roncada, Paola: 2 articles (11/2020 - 05/2020)
4.	Sanguinetti, Maurizio: 2 articles (11/2020 - 05/2020)
5.	Tilocca, Bruno: 2 articles (11/2020 - 05/2020)
6.	Urbani, Andrea: 2 articles (11/2020 - 05/2020)
7.	Hoque, M Nazmul: 1 article (03/2021)
8.	Hossain, M Anwar: 1 article (03/2021)
9.	Islam, Israt: 1 article (03/2021)
10.	Islam, M Rafiul: 1 article (03/2021)

Related Diseases

1.	COVID-19 11/01/2020 - "Improved binding of SARS-CoV-2 Envelope protein to tight junction-associated PALS1 could play a key role in COVID-19 pathogenesis." 05/01/2020 - "Immunoinformatic analysis of the SARS-CoV-2 envelope protein as a strategy to assess cross-protection against COVID-19." 03/01/2021 - "Importantly, higher aa variations observed in the C-terminal domain (CTD) of the E protein, particularly at Ser55-Phe56, Arg69 and the C-terminal end (DLLV: 72-75) may alter the binding of SARS-CoV-2 Envelope protein to tight junction-associated PALS1 and thus could play a key role in COVID-19 pathogenesis. "
2.	Inflammation (Inflammations) 06/30/2023 - "GMI, a fungal immunomodulatory protein, ameliorates SARS-CoV-2 envelope protein-induced inflammation in macrophages via inhibition of MAPK pathway."
3.	Infections 01/06/2023 - "These EVs, initially observed in SARS-CoV-2 envelope protein-expressing cells, are secreted by various SARS-CoV-2-infected cells, including Vero E6, Calu-3, and HPAEpiC cells, undergoing infection-induced pyroptosis. " 07/23/2022 - "To promote viral replication during active infection and viral persistence, the SARS-CoV-2 envelope protein regulates host cell microenvironment including pH and ion concentrations to maintain a high oxidative environment that supports template switching, causing extensive mitochondrial damage and activation of pro-inflammatory cytokine signaling cascades. " 10/01/2020 - "Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine."
4.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/01/2021 - "SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target."
5.	Human Influenza (Influenza) 01/01/2021 - "The repositioning of amantadine derivatives from this influenza target to the SARS-CoV-2 envelope protein was also investigated. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	HMGB1 Protein (HMG1)
3.	Cytokines
4.	BCG Vaccine
5.	Antiviral Agents (Antivirals)
6.	Antigens
7.	Amantadine (Aman)
8.	olmesartan